Piermont Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Piermont Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-19,360	Closed	-$255K	–	225
2018 Q2	$255K	Sell	19,360 -3,600	-16%	-$43.1K	0.08%	218
2018 Q1	$312K	Sell	22,960 -3,778	-14%	-$39K	0.1%	220
2017 Q4	$159K	Sell	26,738 -1,250	-4%	-$8.57K	0.05%	235
2017 Q3	$208K	Sell	27,988 -28,400	-50%	-$236K	0.07%	238
2017 Q2	$528K	Sell	56,388 -10,110	-15%	-$74.2K	0.15%	224
2017 Q1	$484K	Hold	66,498	–	–	0.12%	231
2016 Q4	$492K	Buy	+66,498	New	+$479K	0.11%	225

Other funds holding CCXI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Piermont Capital Management's CCXI Position: Q3 2018 in Review

Piermont Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2018, closing a stake of 19,360 shares — an estimated $255K sold.

Piermont Capital Management first reported a position in CCXI in Q4 2016 and held it in 7 quarters. The position peaked at $528K in Q2 2017. 106 funds tracked by Wall St. Rank hold CCXI as of Q3 2018.

Piermont Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2018 after selling out during the quarter.
Piermont Capital Management sold 19,360 ChemoCentryx, Inc. shares in Q3 2018, an estimated $255K.
Piermont Capital Management first reported a position in ChemoCentryx, Inc. in Q4 2016 and held it in 7 quarters.
Piermont Capital Management's ChemoCentryx, Inc. position peaked at $528K in Q2 2017.
106 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.